Human induced pluripotent stem cells (iPSCs) bearing monogenic mutations have great potential for modeling disease phenotypes, screening candidate drugs, and cell replacement therapy provided the underlying disease-causing mutation can be corrected.
Abstract
Human induced pluripotent stem cells (iPSCs) bearing monogenic mutations have great potential for modeling disease phenotypes, screening candidate drugs, and cell replacement therapy provided the underlying disease-causing mutation can be corrected.
Here we report a homologous recombination (HR) based approach to precisely correct Anemia iPSCs were established using this approach 2 . However, random integrations of a functional copy of the affected gene, especially mediated by viral vectors, could induce oncogenic mutations and thus jeopardize the goal of gene therapy. The precise correction or replacement of mutations at the endogenous loci by homologous recombination (HR) is highly desirable even though the efficiency is extremely low (10 -6 ) in non-cancerous human cells such as human iPSCs. Recently, several studies reported HR-mediated gene addition at a few selective loci in normal or disease-specific human iPSCs [3] [4] [5] [6] [7] . However, this gene addition approach is only suitable for phenotypic correction of loss-of-function mutations, but not for correcting dominant or gain-of-function mutations. The ideal solution is targeted and precise gene correction of the underlying disease-causing mutation, which also ensures the corrected gene will be expressed in
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Toward this, we focused on Sickle Cell Disease (SCD) as a model system to develop methods for precise gene correction of a disease-causing mutation. In the vast majority of SCD patients, the mutation of A>T (also known as β A to β s mutation) in both alleles of the beta-globin (HBB) gene that changes codon 6 from Glu (GAG) to Val (GTG) results in a defective form of adult hemoglobin in oxygen-carrying red blood cells. Although SCD was one of the first described molecular diseases, the goal for treating this monogenic disorder using gene therapy approaches has remained elusive 8, 9 . 
Materials and Methods

Cell culture
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From Human iPSCs were maintained on primary mouse embryonic fibroblasts (PMEFs) as feeder cells using the standard human ESC media. The SCD iPSCs used in this study were generated in an earlier study 13 . The MBP5s1 (abbreviated S1) iPSC line was derived using piggyBac transposition of reprogramming factors into bone marrow stromal cells (MSCs) from an adult patient with SCD at Johns Hopkins Hospital. To adapt to single-cell passaging, the S1 iPSCs were first passaged from PMEFs feeders to feeder-free culture condition using Matrigel (BD Biosciences) and Stemedia Nutristem XF/FF medium (Stemgent) at 1:1 to 1:2 ratio using 0.05% trypsin (Invitrogen) digestion, and then were maintained by this trypsin-passaging and feeder-free culture condition. All patient samples were used per approval from Johns Hopkins University internal review board (IRB) for conducting laboratory research using anonymous human cells. All the iPSC lines described in this report will be provided upon request to Dr. L Cheng, under a standard (uniformed) material transfer agreement with the Johns Hopkins University.
Human 293T cells that were used to validate ZFNs and gene targeting vectors were grown in DMEM high glucose supplemented with 10% fetal bovine serum (FBS).
Characterization of iPSCs after gene targeting and excision
Characterization and chromosome karyotyping (G-banding) of iPSC clones were performed at multiple passages as previously described 3, [13] [14] [15] .
Construction of a donor plasmid vector targeting the endogenous HBB locus
The left and right homology arms were amplified from genomic DNA of SCD fibroblasts (GM02340 In Coriell collection) used in the previous study 15 . The primer sets HBBL-F: 
Gene Targeting Reagents and Experimental Procedure
The CompoZr TM custom designed HBB-ZFNs were obtained from the Sigma-Aldrich. It is now available to the public (CKOZFN1264-1KT). The ZFN pair was designed to target the following DNA sequence in exon 1 of the HBB gene (underlined in Fig. 1A 
Genomic PCR amplification and sequencing of both alleles in SCD iPSCs
Primer set 5'-CGATCACGTTGGGAAGCTATAGAG and 5'-AACATCCTGAGGAAGAATGGGAC were used to amplify the 3.5-kb genomic region surrounding HBB gene for both targeted and non-targeted alleles of S1, cre4, and cre16.
For c36 (targeted) iPSCs, longer extension time was used to amplify both 3.5-kb nontargeted and 5.8-kb targeted alleles. Mixed alleles from these iPSC clones were cloned into a TOPO vector. Then DNA in individual bacterial clones was sequenced to identify specific alleles (targeted or non-targeted).
Southern blot analysis of genomic structure near the HBB locus
Standard Southern blot protocol using DIG-labeled probes was followed as described before 3 . The 3'-probe was amplified from S1 iPSC genomic DNA using primers 5'-GACTGAGAAGAATTTGAAAGGCG and 5'-TCATCAATTCTGCCATAAATGG. The Hyg probe used was the same as described previously 3 .
Genome-Wide SNP concordance analysis
The Omni1_Quad BeadArray chip (Illumina) containing >10 6 probes detecting informative single nucleotide polymorphism (SNPs) was used. The array analysis was Genomic DNA isolated by the Qiagen DNAeasy kit from c36 (after ZFN-mediated HR), S1 iPSCs and their parental somatic cells (MSCs) were analyzed. Based on the ratio of allele intensities, the dis-concordance rate between c36 to S1 iPSCs (two samples of different passages before and after trypsin-adaptation, p17 and p26) or to MSCs (passage 0 and 6) is below 0.04%, which is much lower than the basal error rate level (0.27%). In comparison, the dis-concordance rates between c36/S1 iPSCs to other unrelated iPSCs and between two unrelated CIDR11993 or CIDR10860 controls are ~40%. Therefore, our data suggest that the c36 iPSC genome is essentially identical to the S1 iPSCs or their somatic MSCs.
Erythroblast differentiation from human iPSCs
Human iPSCs were directly differentiated into hematopoietic progenitor cells by a modified embryoid body (EB) formation method as described before 14 . Two weeks after the EB-mediated hematopoietic differentiation, the EB-derived cells were collected and dissociated with accutase treatment. The dissociated cells were cultured in a serum-free medium containing SCF (100 ng/mL), interleukin-3 (10 ng/mL), insulin-like growth factor II (40 ng/ml), erythropoietin (2 U/mL) and dexamethasone (1 µM) for erythroid cell expansion and maturation as previously described 14 . Cells were harvested on day 8 of erythroid expansion and differentiation, and the differentiated cells were analyzed by FACS analysis, cytospin and histology staining as well as RT-PCR for globin expression. 
Results
Specific enhancement of HR efficiency by a novel pair of HBB-ZFNs
Based on our previous studies of gene targeting in human iPSCs and ESCs 3 , we attempted to correct the mutated β s allele in SCD iPSCs. To achieve specific HRmediated gene replacement at the HBB gene, but not at nearby HBD (δ), HBG1 (Aγ), HBG2 (Gγ) and HBE (ε) globin genes (Fig. 1A) , we decided to employ ZFNs that make a specific double-strand-break to stimulate HR near the β s mutation (codon 6) in the HBB gene. After initial screening, a pair of HBB-ZFNs was identified, which targets a bipartite 31-bp sequence (with a 6-bp spacer) in exon 1 (21-bp downstream of the β s mutation) of the HBB gene (Fig. 1A) . We first tested the activity and specificity of this newlydesigned HBB-ZFN pair using a GFP reporter system 3 : DNA sequences from HBB or highly homologous beta-locus genes, HBE, HBD, HBG, were tested as candidate alternative targets of this ZFN pair (Fig. 1A) . Successful HR between the EGIP* reporter (containing a ZFN target sequence) and a truncated GFP (tGFP) donor will restore a full-length GFP gene (Fig. 1B) . Using flow cytometry to measure HR-mediated gene correction in stably transfected 293T cells expressing EGIP*-HBB target, we monitored the number of GFP+ cells after tGFP donor transfection, in the absence or presence of the HBB-ZFN stimulation. Without co-transfection of HBB-ZFN expression vectors, the basal gene correction rate was ~4-5 per million cell events as previously observed 3 (Fig. 1C) . In the presence of the HBB-ZFNs, numbers of GFP+ cells jumped to 0.16% from cells expressing the EGIP* reporter that contains the HBB target sequence: ~350-fold stimulation (Fig. 1C) . On the other hand, the HBB-ZFNs showed no detectable stimulatory activity on EGIP* containing the homologous target DNA from the HBD, HBE and HBG genes, indicating the HBB-ZFNs are highly specific (Fig. 1D) .
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Targeted gene correction of SCD mutation in the endogenous HBB locus
To achieve targeted correction of β s mutation at the HBB locus, we designed a plasmid donor (BD2) to provide wild-type GAG for codon 6 (β A ) and two constitutively expressed drug-selectable genes: PGK-promoter driven hygromycin-resistant gene (PGK-Hyg) for positive selection and EF1α-promoter driven thymidine kinase-GFP fusion gene for counter-selection. The PGK-Hyg selection gene cassette to be inserted into HBB intron 1 was also flanked by loxP sequences for future Cre-mediated excision ( Fig. 2A) . We Our data showed that despite the high transfection efficiency in 293T cells, the BD2 donor vector alone did not generate TI mediated by HR in the silent HBB locus.
However, adding HBB-ZFNs greatly stimulated gene targeting at the endogenous HBB locus (Fig. 2B) . Thus we validated that the BD2 donor is capable of targeting HBB locus, and a pair of 3'-TI primers can be used to screen targeted iPSCs after co-transfection of the BD2 donor vector and two HBB-ZFNs followed by hygromycin and GCV double selections.
We next used a SCD patient-specific iPSC line MBP5s1 (abbreviated as S1) that was previously established by a virus-free method 13 . We first adapted S1 iPSCs to single-cell passaging so that they can survive better after nucleofection. After adaption for 10 continuous passages, the resulting S1 iPSCs at p26 retained iPSC characteristics,
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From pluripotency and a normal karyotype (see below). We then transfected S1 iPSCs cells with the BD2 donor and two HBB-ZFN plasmids by nucleofection, and selected for clones conferring hygromycin and GCV resistance. Proceeding thus, we screened 300 Hyg R -GCV R S1 iPSC clones from multiple HR experiments. First by using PCR for detecting the 3'-junction of TI, we identified 4 candidate clones (Fig. 2C) . One clone, c36, was further expanded and confirmed by Southern blot analysis to bear a TI of the PGK-Hyg cassette into intron 1 on one HBB allele and no additional random integration ( Fig. 2D-E Four out of 24 PCR-screened clones were shown to be negative of 3'-TI (Fig. 2F) , and 3 of those (cre4, cre16 and cre19) were selected and confirmed by Southern blot to be free of the integrated PGK-Hyg gene cassette (Fig. 2G-H) . Sequencing of genomic DNA PCR products using primers in exon 1 and 2 further confirmed the presence of one unmodified β s allele and one corrected (β A ) allele that also bears the leftover loxP site (46 bp including linker DNA) in intron 1, as expected (Fig. 3) .
For
Through two steps of genetic manipulation, we obtained multiple human iPSC clones (c36, cre4, cre16, and cre19) with precise gene correction of the SCD mutation. These clones showed human ESC-like morphology, maintained normal karyotypes and pluripotency under ESC/iPSC culture conditions (Fig. 4) , similar the parental s1 iPSCs.
Our genome-wide SNP concordance analysis did not detect overt difference between the c36 (after HR) and its S1 parental iPSC line (Materials and Methods), although a detailed copy number variation or whole-genome sequencing analysis may provide more information about subtle genetic changes.
Differentiation of patient-derived and gene-corrected SCD iPSCs into erythroid cells
Since the HBB gene is not expressed in the undifferentiated iPSCs, we used differentiated iPSCs to evaluate the restoration of normal beta-globin expression. Human iPSC lines S1, c36, cre4 and cre16 were differentiated into erythroid cells using a twostep serum-free differentiation protocol (Fig. 5A) . During the first step of embryoid body (EB) formation, all the iPSC lines form cystic EBs efficiently. At the end of the second step (erythroid expansion and maturation for 8 days), the differentiated cells expressed CD71+ (94-98%) and CD235a (Glycophrin A, 24-29%) at similar levels (Fig. 5B) , and comparable to normal iPSC lines we previously tested 14 . Giemsa stain confirmed most of the cells in culture were nucleated erythroblasts (Fig. 5C) .
Beta-globin expression in SCD iPSCs after erythroid differentiation
We first used qRT-PCR to measure the total expression levels of the HBB gene (the β s and a corrected allele) as well as the (fetal-type) HBG genes in all SCD iPSCs (S1, cre4
and cre16), differentiated iPSCs at EB stage and at erythroblast stage (Fig. 6A) . While
level of HBG expression in the SCD iPSC-derived erythroblasts (S1-EryB, cre4-EryB, cre16-EryB) is comparable to that in cord blood mononuclear cells (CB-MNC), the level of HBB expression in the erythroblasts is >100-fold lower than that in CB-MNC even though they are ~100-fold higher than those in the EBs (Fig. 6A) . Using a pair of primers located in exon 1 and 3 (blue arrows in Fig. 2A) , we amplified the HBB transcripts from the erythroblasts of gene-corrected SCD iPSCs (c36, cre4 and cre16) by conventional RT-PCR (Fig. 6B) . Then we cloned each PCR product which contains mixed DNA of corrected/wild-type and uncorrected/mutant alleles into TOPO vector and sequenced individual clones. This will tell us the frequencies of both gene-corrected to 40% compared to the uncorrected (and mutated) allele (Fig. 6C) . Our flow cytometry assay using antibodies for adult or fetal hemoglobin proteins confirmed the vast majority of hemoglobin expression in the erythroblasts is fetal-type (HbF), consistent with our qRT-PCR results (Fig. 6D) . Our result is also consistent with two recent reports on erythropoiesis of human iPSCs 17, 18 , indicating that a better culture system is needed to increase erythrocyte maturation, and survival, increase the HBB gene expression, and improve translation from existing HBB transcripts.
Investigation of repressed gene expression of the gene-targeted HBB allele
Our data showed that although HBB transcripts can be detected at a low level in the For c36, there was a 2.2-kb loxP-flanked PGK-Hyg gene cassette inserted in the first exon, excision of which resulted in partial expression of the gene-targeted allele (Fig 6C) .
The PGK-hyg insertion at the first intron (37-bp away from the exon-intron junction) may affect the HBB gene expression in two ways. 1). The PGK-Hyg (intron-less) gene cassette in the same orientation may introduce a cryptic/alternative splicing acceptor. http://www.cbs.dtu.dk/services/NetGene2/) to predict potential cryptic/alternative splicing acceptors in the insertion fragment. We identified several candidates and performed
RT-PCR analysis, but did not detect any alternative transcript around the region (data not shown). 2)
. The PGK promoter may make an antisense transcript that blocks HBB expression. However, no RT-PCR products can be found using several primers covering both strands of HBB exon 1 and the hyg gene sequences. The silencing of the Hyg gene expression (driven by the PGK promoter) in expanded iPSCs is a surprise, but consistent with the observation that c36 iPSCs lost their resistance to hygromycin selection (that was used in the initial clone screening) after expansion in the absence of selection. When we compared the hygromycin expression levels among several iPSCs where the same PGK-Hyg gene cassette is inserted either in the silent HBB gene (such as c36) or in the constitutively active PIG-A gene (such as FPHR iPSCs we published previously 3 ), we found both expanded c36-iPSCs and c36-EryB expressed much lower hygromycin transgene expression than FPHR gene-targeted iPSCs (Fig. 7A) . This suggests epigenetic factors may play a role in silencing the gene-targeted allele including both the inserted PGK-Hyg transgene cassette and adjacent HBB gene.
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One possibility is that the remnant loxP sequence that is 37-bp away from the exonintron junction interferes with the HBB gene expression. To examine other possibilities, we sequenced 3.5-kb sequence covering the whole HBB gene and its flanking genomic regions of all three gene-targeted lines (c36, cre4 and cre16) that had T>A replacement in exon 1 (left panels in Fig. 7B ). Two single nucleotide variants that differ from the parental S1 sequence were found in the targeted allele of all three iPSC lines. The first, located downstream of exon 3 in the gene-targeted HBB allele (middle panels), is a polymorphic nucleotide change (G>T) in the 3' homology arm and likely introduced by the gene-targeting vector containing non-isogenic sequence. This SNP, however, has not been associated with any cis-regulatory elements or SNPs affecting HBB expression.
The second one (A>G) is found only in the targeted allele located downstream of the 3'-end of the right homology arm (right panels in Fig. 7B) , therefore was not contained in the gene targeting donor. This A>G mutation modified the core GATA binding site in the 3'-enhancer of the HBB gene expression 19 . Deletion of the GATA-containing 3'-enhancer element has been shown to reduce HBB expression in transgenic mice 20, 21 .
Since this mutation was only found on the targeted allele of gene-corrected SCD iPSCs (Fig. 7B) , it was likely introduced during the HR-mediated repair and passed from c36 through cre4 and cre16. At present, it is unclear whether this mutation in the GATAcontaining 3' enhancer, or the remaining loxP site in the first intron, or both, is responsible for the reduced expression from the targeted HBB allele.
For personal use only. allele is expressed or silent in undifferentiated iPSCs, the method we described here should apply to correction or replacement in human iPSCs of any specific mutation or even a SNP locus. During the revision of this report, two other studies reported the correction of single mutations in human iPSCs 24, 25 . Together with our study reported here on gene correction of the SCD mutation, these papers show the feasibility regardless the underlying gene is expressed or silent in human iPSCs.
Numerous studies have reported that homology-directed repair is often much less efficient when a silent gene is targeted 26, 27 . This also explains our observed low efficiency of targeting the HBB gene even in the presence of a pair of ZFNs, as compared to that of a constitutive gene (PIG-A) we previously published 3 . The HBBZFNs used here is 50% less efficient than the PIG-A ZFNs measured by the similar GFP* reporter assays (Fig. 1B) , which could also contribute to a lower gene targeting of the HBB gene in human iPSCs. With an improved ZFN technology 28 or other emerging methods such as TALEN 29 , we will likely find a high-affinity ZFN or TALEN at or near the SCD mutation in HBB, without cutting the nearby HBD, HBG and HBE genes.
For However, the transgene expression cassette inserted into an intron can be easily excised out via the Cre-loxP system, and the endogenous gene expression can be largely restored after excision.
Although in most applications we do not need to completely restore expression level of the corrected allele to the same level of the uncorrected alleles, it is better for us to understand why only a partial restoration (25% to 40%) of the corrected allele in cre4 and cre16 iPSCs after the loxP excision (Fig. 6B) . Currently, we could not distinguish the following two possibilities and more studies are needed. 1). The presence of one copy of loxP left in the first intron interfered with the endogenous HBB gene expression.
2). A genetic mutation in the GATA site of HBB 3'-enhancer (likely introduced in iPSC HR and/or clonal selection process) is responsible for the reduction of erythroid-specific
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From HBB expression. For the former possibility, we may use piggyBac DNA transposition to achieve zero-footprint excision of the selection gene cassette 30 . For the latter possibility, our study highlights the importance to conduct high-resolution whole-genome sequence analysis. Although the HR-gene targeting did not show increased mutation rates as compared to other proliferating cell populations in studies published by us and others 3, 4, 24 , previous employed methods of chromosomal karyotyping, SNP arrays and even exome sequencing may not be sufficient to detect small changes across the whole genome. With recent cost reduction of whole-genome sequencing that is now affordable to an average lab, it is now possible to sequence the whole genome of selected iPSC clones after ZFN-mediated gene targeting.
Although in this study we focused on site-specific gene correction of a defined single mutation in the HBB gene, our functional analysis and relevance to future gene therapy is hampered by the fact that existing culture methods only allow us to generate nucleated erythrocytes that express gamma-globin instead of beta-globin proteins.
Nevertheless, HBB transcripts can be detected, albeit at a low level, by RT-PCR in differentiated erythroblasts derived from parental S1 and corrected cre iPSC lines (Fig.   6 ). This allowed us to show that the corrected HBB allele after gene targeting can be
expressed. An ideal iPSC-based gene therapy for SCD will require both precise correction of disease-causing mutation while preserve cis-regulatory elements regulating HBB expression, and complete switching from fetal-type globin to adult-type globin.
Therefore, further genetic and epigenetic studies are required to better understand globin gene switching in the iPSC system and to improve hematopoietic differentiation into more mature/enucleated erythroid cells from gene-corrected iPSCs, if they are going to be used for cell therapy. In addition, reproducible in vivo models to generate transplantable hematopoietic progenitor cells and red blood cells from human iPSCs and 31, 32 , before we can assess the pre-clinical feasibility of the combined cell and gene therapy approach using gene corrected iPSCs derived from SCD patients.
Despite these hurdles to be overcome in future years, our current study demonstrates that it is now possible to correct a specific point or small mutation at its endogenous locus in patient-specific iPSCs, and also to restore gene expression of the corrected form upon cell differentiation. The gene targeting methodology we reported here would extend the use of various iPSC lines containing disease related mutations in genes that are either expressed or silent in human iPSCs. 
